4SC AG — Board/Management Information 2012

May 2, 2012

News Details

Corporate | 2 May 2012 10:04

Press Release 4SC AG: Dr Jörg Neermann announces resignation from Supervisory Board of 4SC AG

4SC AG / Key word(s): Change of Personnel/Miscellaneous

02.05.2012 / 10:04

---

Press Release

4SC AG: Dr Jörg Neermann announces resignation from Supervisory Board

Planegg-Martinsried, Germany, 2 May 2012 – 4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that Dr Jörg Neermann has informed the company that he will resign from his position as chairman and member of the Supervisory Board of 4SC AG effective 31 May 2012. Dr Neermann is resigning of his own accord and for personal reasons. Dr Neermann has been a member of the Supervisory Board of 4SC AG since 3 August 2000 and previously had been a member of the Advisory Board of the predecessor company, 4SC GmbH.

4SC thanks Dr Neermann for his many years of commendable service and his dedication to the work of the Supervisory Board. Dr Thomas Werner, deputy chairman of the Supervisory Board of 4SC AG, will be assuming the position of chairman of the Supervisory Board on an interim basis from 1 June 2012. Following the departure of Dr Neermann, the Supervisory Board will initiate proceedings for the election of a new Supervisory Board chairman and deputy chairman as soon as possible.

Dr Thomas Werner, deputy chairman of the 4SC Supervisory Board, said: 'Dr Neermann has made an outstanding contribution to the company's prestige and to the establishment of 4SC as one of Germany's most innovative biotechnology companies. We regret that Dr Neermann will be leaving us and thank him for his dedication over the years and his successful work as chairman of the 4SC Supervisory Board.'

Dr Ulrich Dauer, Chief Executive Officer of 4SC AG, commented: 'Dr Neermann has contributed invaluable support to and had decisive impact on the successful development of 4SC for over 13 years. Not only as an investor in all of the company's rounds of venture capital financing, from the initial financing in 1999 to the public listing in 2005, but also as a member – and, from 2003, as chairman – of the 4SC Supervisory Board. On behalf of the entire 4SC Management Board and the entire company, I wish to thank Dr Neermann for his magnificent contribution to 4SC's success and for his dedicated and constructive collaboration as a friend of our company. I wish him all the best for the future.'

Ends

About 4SC

The Group managed by 4SC AG (ISIN DE0005753818) discovers and develops targeted, small-molecule drugs for treating diseases with a high unmet medical need in various autoimmune and cancer indications. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The Company's balanced pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with leading pharmaceutical companies. Founded in 1997, 4SC had 96 employees at the end of 2011. 4SC AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.

Legal Note

This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors.

For more information please visit www.4sc.com or contact:

4SC

Jochen Orlowski, Investor Relations & Public Relations

jochen.orlowski(at)4sc.com, Tel.: +49 (0) 89 70 07 63 66

MC Services

Raimund Gabriel

raimund.gabriel(at)mc-services.eu , Tel.: +49 (0) 89 21 02 28 30

Mareike Mohr

mareike.mohr(at)mc-services.eu, Tel.: +49 (0) 89 21 02 28 40

The Trout Group (USA)

Chad Rubin

Crubin(at)troutgroup.com, Tel.: +1 646 378 2947

End of Corporate News

---

02.05.2012 Dissemination of a Corporate News, transmitted by DGAP – a company of EquityStory AG.

The issuer is solely responsible for the content of this announcement.

DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language:	English
Company:	4SC AG
	Am Klopferspitz 19a
	82152 Martinsried
	Germany
Phone:	+49 (0)89 7007 63-0
Fax:	+49 (0)89 7007 63-29
E-mail:	public@4sc.com
Internet:	www.4sc.de
ISIN:	DE0005753818
WKN:	575381
Listed:	Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart

End of News	DGAP News-Service

- - -
167634  02.05.2012